Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of JCXH-221 in Healthy Volunteers
NCT05743335Phase 1Completed
- Sponsor
- Immorna
- Start
- Mar 2023
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing JCXH-221 with Placebo (2 arms). Primary endpoints: Serious Adverse Event frequency at 12 months, Injection site reaction frequency at 7 days and 4 more. Started Mar 2023; status: completed.
02
Drugs
JCXH-221
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05743335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05743335.